Memantine is commonly used for the treatment of moderate-to-severe Alzheimer’s disease. It has also been investigated for potential utilization in opioid use disorder (OUD). The objective of this systematic review is to assess the evidence available to determine the safety and efficacy of memantine as treatment for OUD. After assessing studies appropriate for the objective, one single-blind and five double-blind, placebo-controlled trials were included. Based on the reviewed literature, memantine appears most beneficial as an adjunctive treatment for OUD when combined with methadone or buprenorphine, but not naltrexone. Memantine was well tolerated with similar rates of adverse effects between treatment groups. Larger studies with longer periods of treatment and follow-up are needed to support the use of memantine in the management of OUD.
Source: Journal of Substance Abuse Treatment, December 2019